New research has found that stress-induced hormones produced by the brain can increase an individual’s risk of developing Alzheimer’s disease and accelerate the development of Alzheimer’s in individuals already suffering from the disease.
While previous reports have linked elevated levels of stress with an increased risk in an individual developing dementia, this study is the first to discover the precise mechanism that causes stress-induced Alzheimer’s disease.
When the brain is stressed, it produces steroids that can inhibit general brain activity. One of such steroids, allopregnanolon, was the subject of a study led by Swedish researcher Sara K. Bengtsson.
In order to test how and why stress can lead to dementia later in life, the research team conducted a laboratory experiment on mice genetically predisposed to developing Alzheimer’s disease. The mice were treated chronically with elevated allopregnanolone levels, comparable to those caused by mild stress. After a period of no steroid treatment, the mice were tested for learning and memory.
The mice with elevated levels of the stress steroid experienced impaired memory and learning in the earliest stages of Alzheimer’s development, when they normally would not display these symptoms. The brains of the mice also displayed higher levels of beta-amyloids, proteins that form plaques between nerve cells in the brains of individuals with Alzheimer’s disease. The researchers noted that a similar acceleration of Alzheimer's disease in humans due to chronic stress could mean the difference between living independently and requiring professional care.
Bengtsson concluded that allopregnanolone is an important link in the mechanism behind stress-induced Alzheimer’s disease, but that further studies would be required to uncover the full extent of its influence.
The National Institutes of Health recently released recommendations providing a framework for an Alzheimer’s disease research agenda that was develope...
End of Life, Federal Agency Activity, Managed Risk, Medication Management, Memory Care Best Practices and Research
Federal and state policies generally encourage the use of available generic drug products as do private payers such as insurers and others, which is w...
The National Institutes of Health is encouraging people to volunteer for clinical trials that look for ways to prevent, slow and treat Alzheimer’s dis...
Formalizing standards around memory care is the top priority for the newly formed ALFA Memory Care Roundtable. The group, which met in person for the ...
Cognitive aging is a natural process associated with advancing years and the Institute of Medicine recently released a report assessing the public hea...